Phase IV Trials Inadequate Response To HCV Drug Concerns – FDA Cmte.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Skepticism over the utility of Phase IV commitments shaped an FDA advisory committee’s recommenddations on development of new hepatitis C treatments.